Singulair - Montelukast sodium

Singulair Montelukast sodium Merck Oral granules Granule... 

There is also continuous interaction throughout the review process. For example, over roughly six years, the sponsor, Merck Research Laboratories of West Point, Pa., and the FDA had several face-to-face meetings and about 28 teleconferences regarding the asthma drug Singulair (montelukast sodium). 

Several commercial products have been produced via Heck reactions on a scale in excess of one ton year"1 [43]. The sunscreen agent 2-ethylhexyl-p-methoxycinna-mate has been synthesized on a pilot scale by using Pd/C as the catalyst [44]. Albermarle produces Naproxen via a Heck reaction of 2-bromo-6-methoxy-naphthalene with ethylene, followed by carbonylation of the product [45]. A key step in the production of Singulair (montelukast sodium), a leukotriene receptor antagonist for treatment of asthma, is Heck reaction of methyl 2-iodobenzoate with an allylic alcohol to give a ketone [43]. 

MK-0476 (Singulair, Montelukast Sodium, 34) and Its Precursors. Because the series of compounds exemplified by MK-0571, MK-0679, and MK-0476 (34-36) contain mi-metics for the three regions of LTD, (lipid, acid, peptide) they may be viewed as leukotri-ene analog antagonists. However, unlike the... 

Singulair (Montelukast sodium). Merck Co., Inc. US Prescribing information, April 2007. 

USAN- Montelukast sodium Trade Name Singulair Merck... 

Monopril fosinopril. monosulfiram [ban] (sulfiram [inn]) is an ethylthiocarbonic acid derivative with ANTIFUNGAL properties and can be used as parasiticide and fungicide, montelukast [ban, inn] (montelukast sodium [usan] Singulair ) is a chloroquinolinyl derivative, a (LTD ) LEUKOTRIENE receptor antagonist, which can be used as an ANTIASTHMATIC. 

MK 476 Montelukast monosodium salt Montelukast sodium Singulair. Selective leukotriene 04 receptor antagonist. Used as an antiasthmatic. Merck 4 Co.Inc. 

Balani, S.K. Metabolic profiles of montelukast sodium (Singulair), A potent cysteinyl leukotrienei receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 1997, 25, 1282-1287. 

Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995 73 191-201. 

A quinoline compound called montelukast sodium is the active ingredient in SINGULAIR, which is the Merck dmg for asthma. 

Montelukast sodium (1, 2-[l-[[(lR)-l-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulphanyhnethyl] cyclopropyl]acetic acid, sodium salt, Singulair , originator Merck Co.), a once-a-day oral antagonist of leukotriene D4 (LTD4) was selected for chnical development in 1991, and introduced in 1997 for the treatment of both adult and pediatric chronic asthma. This compound is recognized as one of the most significant advances in asthma therapy in the last 25 years [1] and is commonly used for the treatment of nocturnal asthma. 

---